MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.16151

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2020

Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan.

Yoshizaki Tetsuya, Morisawa Toshiyuki, Fujinami Maho, Matsuda Tatsuya, Katayama Norio, Inoue Kazuki, Matsumoto Masanori, Ikeoka Seitaro, Takagi Megumi, Sako Tomoya, Momose Kenji, Noda Mari, Eguchi Takaaki, Okada Akihiko

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Vonoprazan, a potassium-competitive acid blocker, is used for acid-related diseases. Occasionally, small white protrusions called "stardust" gastric mucosa have been detected in the stomachs of some patients taking vonoprazan.

AIMS: To determine the incidence of, and risk factors for, stardust gastric mucosa potentially induced by vonoprazan

METHODS

In this study, we enrolled 19 503 patients who underwent endoscopy at our hospital between 2016 and 2019. Using propensity score matching, we retrospectively compared patients who received and did not receive vonoprazan. The two groups were matched for age, sex, history of proton pump inhibitor use, and atrophic gastritis.

RESULTS

After 1:1 propensity score matching, each group comprised 2516 patients. Stardust gastric mucosa was detected significantly more often in the stomachs of patients receiving vonoprazan than those who had not received vonoprazan (4.9% vs 0.2%, P < 0.001). Its location was 70.7% in the upper third of the stomach, 29.3% in the middle third and none in the lower third. Histologically, this lesion had a mucus pool within a dilated duct surrounded by flattened glandular epithelium. The cumulative incidence rate of stardust gastric mucosa at 1, 2 and 3 years was 4.6%, 16.5% and 26.2%, respectively. The factors independently associated with the presence of stardust gastric mucosa were >205 days of vonoprazan oral intake (odds ratio [OR]: 6.99, 95% confidence interval [CI]: 4.60-10.88) and female sex (OR: 1.75, 95% CI: 1.20-2.58).

CONCLUSIONS

Stardust gastric mucosa appeared more frequently in the stomachs of patients taking vonoprazan.

Для цитирования: Yoshizaki Tetsuya, Morisawa Toshiyuki, Fujinami Maho, Matsuda Tatsuya, Katayama Norio, Inoue Kazuki, Matsumoto Masanori, Ikeoka Seitaro, Takagi Megumi, Sako Tomoya, Momose Kenji, Noda Mari, Eguchi Takaaki, Okada Akihiko. Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan.. Alimentary pharmacology & therapeutics. 2020. DOI: 10.1111/apt.16151.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.